LABT.US Lakewood-Amedex Biotherapeutics Inc. Common Stock
- Market cap
- USD 669K
- P/E
- -
- P/B
- 0.15x
- ROE
- -216.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LABT.US undervalued?
Graham numberThe Graham number of Lakewood-Amedex Biotherapeutics Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lakewood-Amedex Biotherapeutics Inc. Common Stock fundamental analysis
No fundamental analysis for Lakewood-Amedex Biotherapeutics Inc. Common Stock yet.
Lakewood-Amedex Biotherapeutics Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known …
Full company profileLakewood-Amedex Biotherapeutics Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lakewood-Amedex Biotherapeutics Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.64M | -4.03M | -3.77M | -9.35M |
| EBITDA | -8.15M | -4.73M | -3.63M | -9.18M |
| Net Income | -8.28M | -4.86M | -3.85M | -9.39M |
| EPS | -12 | -6.94 | -2.76 | -6.61 |
| Balance Sheet | ||||
| Total Assets | 6.89M | 1.07M | 482K | 4.96M |
| Total Liabilities | 2.34M | 661K | 2.45M | 629K |
| Shareholders' Equity | 4.56M | 410K | -1.96M | 4.33M |
| Cash & Short-term Investments | 2.53M | 681K | 236K | 4.58M |
| Total Debt | - | - | 1.66M | 102K |
| Cash Flow | ||||
| Operating Cash Flow | -6.82M | -5.72M | -1.94M | -4.91M |
| Capital Expenditure | 0.00 | 1.85K | 0.00 | 0.00 |
| Free Cash Flow | -6.82M | -5.73M | -1.94M | -4.91M |
| Ratios | ||||
| ROE | -181.7% | -1,185.4% | - | -216.8% |
| ROA | -120.1% | -453.5% | -798.9% | -189.3% |
| Debt to Equity | - | - | - | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lakewood-Amedex Biotherapeutics Inc. Common Stock dividends
Lakewood-Amedex Biotherapeutics Inc. Common Stock has not paid dividends in the last 3 fiscal years.
Last stock split: 1:10 on Jun 22, 2026.
Who owns Lakewood-Amedex Biotherapeutics Inc. Common Stock
- Insiders 39.47%
- Institutions 5.75%
- Public & others 54.78%
- Shares outstanding 2.37M
- Free float 848K
Top funds holding LABT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 43.3K | 1.83% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 1.49K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding LABT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Marex Group Ltd | 48.2K | 2.03% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 44.8K | 1.89% | 0.00% | Jun 2026 |
| UBS Group AG | 4.10K | 0.17% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 624.00 | 0.03% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 138.00 | 0.01% | 0.00% | Jun 2026 |
| Ronald Blue Trust, Inc. | 11.00 | 0.00% | 0.00% | Jun 2026 |
Lakewood-Amedex Biotherapeutics Inc. Common Stock company profile
- Company name
- Lakewood-Amedex Biotherapeutics Inc. Common Stock
- Ticker
- LABT.US
- Exchange
- USA Stocks
- Listed since
- Apr 23, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 8031 Cooper Creek Blvd., University Park, FL, United States, 34201
- Phone
- 941 225 2515
- Website
- lakewoodamedex.com
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Lakewood-Amedex Biotherapeutics Inc. Common Stock management
5- Dr. Kelvin Cooper Ph.D.CEO, SVP of Research & Development and Director · born 1956
- Mr. Peter F. CeccacciCFO & VP of Administration · born 1955
- Dr. Thomas Balzer M.D., Ph.D.Chief Medical Officer & SVP of Clinical Development · born 1960
- Ms. Tara EndressProject Manager & Accounting Manager
- Daniel Kontoh-BoatengInvestor Relations